SLE患者血清中SARS-CoV抗体阳性原因分析

为了探讨严重急性呼吸综合征(SARS)冠状病毒(SARS-CoV)抗体测定在系统性红斑狼疮(SLE)患者中的假阳性问题,应用酶联免疫吸附试验(ELISA)和荧光定量RT-PCR技术检测了66例正常对照和31例SLE患者血清中SARS-CoV抗体的阳性率。结果,66例正常对照中,IgM抗体均阴性,IgG抗体的阳性率为3.0%(2/66);31例SLE患者中,IgM抗体和IgG抗体阳性率分别为29%(9/31)和58.1%(18/31),IgG抗体和IgM抗体同时阳性为22.6%(7/31)。经RTPCR检测,上述阳性病例均为阴性。结论:用非纯化抗原制备的ELISA试剂盒测定SLE患者的SARS-CoV抗体,可能出现假阳性,两种抗体同时测定可降低诊断的假阳性率,提高诊断的特异性。在SLE患者中出现假阳性的原因可能与包被的抗原有关。     

肿瘤患者血清中SARS-CoV抗体阳性原因分析

探讨SARS冠状病毒(SARS—CoV)抗体在SARS病原学诊断中的特异性及其在肿瘤患血清中的假阳性问题。应用ELISA和荧光定量RT-PCR技术检测了111例正常对照和40例肿瘤患血清中SARS—CoV抗体的阳性率。在111例正常对照中,IgM抗体均阴性,IgG抗体的阳性率为3．6％(4／111);IgG抗体诊断SARS的特异性为96．4％,两种抗体同时阳性诊断SARS的特异性为100％。40例肿瘤患中,IgM抗体均阴性,IgG抗体阳性率17．5％(7／40)。经RT—PCR检测,上述肿瘤患阳性病例均为阴性。结果表明,同时测定SARS—CoV的两种抗体可降低诊断的假阳性率,提高诊断的特异性。用非纯化SARS—CoV抗原制备的ELISA试剂盒测定肿瘤患的SARS—CoV抗体,可能出现假阳性。在肿瘤患中出现假阳性的原因可能与包被的抗原有关。     

胶体金免疫层析法检测新型冠状病毒IgM/IgG抗体的临床评价与应用

新型冠状病毒(SARS-CoV-2)感染暴发流行已成为全球公共卫生事件,急需快速有效的现场诊断试剂。为探讨SARS-CoV-2病毒IgM/IgG抗体胶体金免疫层析法检测效果及临床应用价值,本研究选取304例新冠肺炎临床诊断病例、114例SARS-CoV-2核酸检测阴性的正常人(138)及其他发热伴呼吸道症状病例(64),采用胶体金法对采自上述病例的血浆或血清标本进行IgM和IgG抗体检测,并选取部分病例进行了全血和血浆或血清标本的检测同源性比较,进一步对304例临床诊断病例的病毒核酸、IgM/IgG抗体的时间分布进行了分析。结果显示,304临床诊断病例中,SARS-CoV-2核酸检测阳性病例为105例,胶体金法检测SARS-CoV-2 IgM和IgG抗体的敏感性分别为76.2%(80/105)和86.6%(91/105),IgM/IgG抗体阳性总体符合率为96.1%(101/105);核酸、抗体均为阴性者为73例;其余126例临床诊断病例中,IgM阳性率为69.2%(87/126),IgG阳性率为98.3%(125/126),IgM/IgG总体符合率为100%(126/126)。健康人和其他发热病人中,IgM和IgG检测特异性分别为99%(200/202)和98%(198/202)。同源全血与血浆或血清标本抗体检测结果的总符合率为99%,显示两者具有高度一致性。本研究提示,胶体金法检测SARS-CoV-2抗体有较好的敏感性及特异性,可用于临床辅助诊断和流行病学调查等,具有较广泛的应用场景,在新冠肺炎疫情防控中具有一定的应用价值。     

SLE患者血清中SARS—CoV抗体阳性原因分析

为了探讨严重急性呼吸综合征(SARS)冠状病毒(SARS—CoV)抗体测定在系统性红斑狼疮(SLE)患者中的假阳性问题,应用酶联免疫吸附试验(ELISA)和荧光定量RT—PCR技术检测了66例正常对照和31例SLE患者血清中SARS—CoV抗体的阳性率。结果,66例正常对照中,IgM抗体均阴性,IgG抗体的阳性率为3．0％(2／66);31例SLE患者中,IgM抗体和IgG抗体阳性率分别为29％(9／31)和58．1％(18／31),IgG抗体和IgM抗体同时阳性为22．6％(7／31)。经RT—PCR检测,上述阳性病例均为阴性。结论：用非纯化抗原制备的ELISA试剂盒测定SLE患者的SARS—COV抗体,可能出现假阳性,两种抗体同时测定可降低诊断的假阳性率,提高诊断的特异性。在SLE患者中出现假阳性的原因可能与包被的抗原有关。     

中国新疆维吾尔自治区不明原因发热人群中Tahyna病毒感染状况调查

本研究通过对新疆地区不明原因发热人群血清Tahyna病毒抗体进行检测,以了解Tahyna病毒在当地的感染状况及分布特征。通过间接免疫荧光方法对新疆维吾尔自治区南部喀什地区、北部伊犁地区742例不明原因发热患者急性期血清标本进行Tahyna病毒抗体检测,并对IgM抗体阳性标本平行进行Tahyna病毒、Snowshoe hare病毒和Inkoo病毒三种抗原性相似的布尼亚病毒的蚀斑减少中和试验。研究结果显示新疆南部喀什地区采集不明原因发热患者急性期血清中,IgM抗体阳性率5.3%,IgG抗体阳性率18.3%;新疆北部伊犁地区采集的急性期患者血清标本中并未发现TAHV IgM抗体阳性;蚀斑减少中和试验结果显示,TAHV IgM抗体阳性患者血清中Tahyna病毒中和抗体滴度较其它两种布尼亚病毒中和抗体滴度升高明显。本研究证实新疆南部地区不明原因发热人群存在Tahyna病毒的急性感染和既往感染,为相关疾病的进一步监测提供基础。     

血中检测SARS冠状病毒N蛋白在SARS实验室早期诊断中的作用

为明确严重急性呼吸综合症(SARS)冠状病毒N蛋白在SARS实验室早期诊断中的作用,通过微量中和试验及酶联免疫方法、间接免疫荧光法检测疑似病人恢复期血清(大于28天)中SARS-IgG抗体,确诊SARS患者。同时收集发病不同时期SARS及普通发热病人血清,利用酶联免疫方法检测SARS-CoVN蛋白,并与荧光定量PCR早期诊断方法相比较。共检测：广州地区2003年12月～2004．年1月新发4例确诊SARS患者不同时期的血液和咽漱液标本;恢复期血清SARS-CoV中和抗体阳性病人不同时期的血清46份;广州地区2003年1月～4月临床确诊SARS患者159例的血清和56例疑似患者血清;非SARS普通发热病人血清97份;正常人体检血清100份。结果：4例新发SARS患者的不同时期标本中,3例患者急性期血均检出N蛋白,优于常用的荧光定量PCR检测方法。46份SARS-CoV中和抗体阳性的血清标本,N蛋白检出率为100％。159例临床确诊病例中,发病早期5天以内SARS-CoVN蛋白的检出率为92．3％,随后呈现逐步下降的趋势,在发病第18天仍可检出。56例临床疑似患者发病早期也有23．2％检出率。而97例普通发热病人及100份正常人血清中均未能检测出SARS-CoVN蛋白。表明在血清中检测SARS冠状病毒N蛋白的方法敏感性和特异性都好,对SARS实验室早期诊断具有重要作用。     

念珠菌特异性IgM和IgG抗体在肺念珠菌病中的诊断价值

目的:评价念珠菌特异性IgM和IgG抗体在肺念珠菌病中的诊断价值。方法:入选2017-09-01～2018-03-31住院患者76例,其中临床诊断肺念珠菌病患者8例、拟诊诊断肺念珠菌病患者13例、非念珠菌病患者55例(曲霉菌病患者12例、非真菌病患者28例、未确定病原菌患者15例);用胶体金法念珠菌特异性IgM和IgG抗体检测患者血液标本,与血清G实验和肺泡灌洗液(BALF)G实验比较,分析IgM和IgG抗体检测在诊断肺念珠菌病中的价值。结果:76例患者全部行IgM和IgG抗体检测,IgM抗体检测阳性33例,IgG抗体检测阳性22例;38例患者行血清G实验检测,阳性1例;35例患者行BALF G实验检测,阳性15例。检测灵敏度、特异度和Youden指数,IgM抗体检测分别为100.0%、64.2%和0.642,IgG抗体检测分别为87.5%、77.9%和0.654,血清G实验分别为0%、97.1%和-0.029,BALF G实验分别为83.3%、65.4%和0.487。结论:IgM抗体检测诊断肺念珠菌病的灵敏度高,可作为高危患者的筛查指标;IgG抗体检测灵敏度和特异度均较高,可作为诊断肺念珠菌病的指标。     

发热伴血小板减少综合征患者血清中核蛋白抗体的动态变化

目的:观察新发传染病发热伴血小板减少综合征(SFTS)的病原体新型布尼亚病毒(SFTSV)核蛋白(NP)IgM和IgG型抗体在SFTS患者外周血中的变化规律,为疾病的早期诊断和发病机制的认识提供依据.方法:用ELISA方法检测28例SFTS患者不同病程阶段血清中NP特异性IgM、IgG抗体.结果:①28例SFTS患者中,IgM阳性检出率为89.3 ％(25/28),IgG阳性检出率为85.7 ％(24/28).②IgM和IgG均在发病5天后开始出现,随着病程延长血清中抗体水平逐渐上升,其峰值出现在发病2周左右.③死亡组患者的抗体检出时间迟于痊愈组患者,且抗体水平低下.结论:①在SFTSV感染早期,SFTS患者血清中NP特异性抗体IgG和IgM的变化趋势一致,NP特异性抗体IgG和IgM一样是SFTS早期诊断的重要指标.②因疾病严重而死亡的患者,抗体出现延迟、抗体水平低下可能与患者细胞免疫系统严重受损及多脏器功能障碍有关,致使机体体液免疫应答减退或应答无能.③抗体出现延迟且抗体水平低下可能是病情严重患者预后不良的预测指标.     

GICA和CLIA联合检测SARS-CoV-2特异性抗体的检测策略研究

评价胶体金免疫层析法(GICA)与化学发光法(CLIA)联合检测对降低新型冠状病毒(SARS-CoV-2)特异性抗体假阳性的效果。收集2020年1月22日至2020年3月5日就诊于川北医学院附属医院及南充市中心医院的19例SARS-CoV-2确诊患者不同时段的血清33份,55例非SARS-CoV-2、其他病原体感染及自身免疫性疾病患者的血清55份,采用GICA和CLIA分别对血清SARS-CoV-2 IgM、IgG进行检测,并对结果进行分析。GCIA检测SARS-CoV-2 IgM、IgG的敏感性分别为100.0%、94.74%,与CLIA(92.86%和100.0%)比较没有差异(P>0.05);GCIA检测SARS-CoV-2 IgM、IgG的特异性分别为70.91%、74.55%,明显低于CLIA的特异性(98.18%和89.09%)(P<0.01);两种方法检测SARS-CoV-2 IgM、IgG结果具有一致性(P<0.001),Kappa值分别为0.434,0.406;ROC曲线分析发现,GCIA检测SARS-CoV-2 IgM、IgG的AUC分别为0.855、0.846,明显低于CLIA(0.955和0.945)(P<0.05)。两种方法联合检测SARS-CoV-2 IgM、IgG的敏感性分别为92.86%、94.74%,特异性分别为100.0%、100.0%;ROC曲线分析显示,联合检测SARS-CoV-2 IgM、IgG的AUC分别为0.964、0.974,高于两种方法的单独检测。GICA和CLIA联合检测能有效提高SARS-CoV-2 IgM和IgG的检测特异性,值得临床推广应用。     

新型布尼亚病毒抗体检测方法的建立及初步应用

目的:建立新型布尼亚病毒IgG抗体ELISA检测方法。方法:用基因工程重组表达的新型布尼亚病毒NP抗原包被酶联板,建立间接ELISA法检测新型布尼亚病毒IgG抗体,并进行特异性和灵敏度评价,健康人群中检测结果计算临界值(均值+3标准差)。检测70例发热伴血小板减少综合征患者恢复血清和69份健康人血清样品。结果:在70份患者血清样品中,检测出新型布尼亚病毒IgG抗体阳性51例,阳性率为72.14%(51/70);69份健康人血清样品中,检测出1份阳性,特异性为98.6%(1/69)。结论:建立的新型布尼亚病毒IgG抗体ELISA检测方法特异性强、灵敏度高,可用于新型布尼亚病毒感染的检测及流行病学调查。     

Extremely low exposure of a community to severe acute respiratory syndrome coronavirus: false seropositivity due to use of bacterially derived antigens

Estimates of seropositivity to a new infectious agent in a community are useful to public health. For severe acute respiratory syndrome (SARS), the figures are conflicting. Herein, we screened 12,000 people in a community stricken by SARS 10 months previously and found 53 individuals (0.44%) who had immunoglobulin G antibodies to the SARS coronavirus (SARS-CoV) nucleocapsid (N) produced in bacteria. However, only seven of these (group 1) had sera which also reacted with the native N antigen expressed in SARS-CoV-infected Vero cells, N-transfected 293T cells, and tissues of infected SARS patients. Of these, six individuals had had SARS previously. The remaining person, as well as the 46 other individuals (group 2), were healthy and had no history of SARS. Group 1 antibodies recognized epitopes located slightly differently in N from those of group 2 antibodies, and a mouse hybridoma antibody resembling the former type was generated. Unusually, group 2 antibodies appeared to recognize cross-reactive bacterial epitopes that presumably were posttranslationally modified in eukaryotes and hence were probably not induced by SARS-CoV or related coronaviruses but rather by bacteria. The N antigen is thus highly unique. The extremely low rate (0.008%) of asymptomatic SARS infection found attests to the high virulence of the SARS-CoV virus.     

Antibody responses to individual proteins of SARS coronavirus and their neutralization activities

A novel coronavirus, the severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), was identified as the causative agent of SARS. The profile of specific antibodies to individual proteins of the virus is critical to the development of vaccine and diagnostic tools. In this study, 13 recombinant proteins associated with four structural proteins (S, E, M and N) and five putative uncharacterized proteins (3a, 3b, 6, 7a and 9b) of the SARS-CoV were prepared and used for screening and monitoring their specific IgG antibodies in SARS patient sera by protein microarray. Antibodies to proteins S, 3a, N and 9b were detected in the sera from convalescent-phase SARS patients, whereas those to proteins E, M, 3b, 6 and 7a were undetected. In the detectable specific antibodies, anti-S and anti-N were dominant and could persist in the sera of SARS patients until week 30. Among the rabbit antisera to recombinant proteins S3, N, 3a and 9b, only anti-S3 serum showed significant neutralizing activity to the SARS-CoV infection in Vero E6 cells. The results suggest (1) that anti-S and anti-N antibodies are diagnostic markers and in particular that S3 is immunogenic and therefore is a good candidate as a subunit vaccine antigen; and (2) that, from a virus structure viewpoint, the presence in some human sera of antibodies reacting with two recombinant polypeptides, 3a and 9b, supports the hypothesis that they are synthesized during the virus cycle.     

Anti-VP1 and anti-VP2 antibodies detected by immunofluorescence assays in patients with acute human parvovirus B19 infection

Acute human parvovirus B19 infection is followed by an antibody response to the structural proteins of the viral capsid (VP1 and VP2). We used 80 sera collected from 58 erythema infectiosum and 6 transient aplastic crisis patients to test IgM and IgG antibodies against these two proteins in an immunofluorescence assay (IFA) using Sf9 cells infected with recombinant baculovirus expressing either VP1 or VP2 antigen. Although less sensitive than IgM capture enzyme immunoassay using native antigen (MACEIA), we could detect anti-VP1 or anti-VP2 IgM antibodies by IFA in 49 patients with acute infection (76.6%). Detection of IgG anti-VP1 and anti-VP2 by IFA, however, was as sensitive as IgG detection by indirect enzyme immunoassay. By applying IgG avidity IFA to sera of the 15 IgM IFA negative patients we were able to confirm acute infection in further 12 cases by IFA. Overall, acute infection was confirmed by IFA in 61 (95.3%) of the 64 patients.     

检测人血清中SARS冠状病毒IgG抗体的ELISA方法建立及其应用

为了建立方便、敏感和特异的SARS病毒血清学诊断方法,利用PQE30表达系统在大肠杆菌M15中分段高效表达了SARS病毒N蛋白.通过金属鏊合亲和层析纯化了目的蛋白N-1和N-2,Western blot结果显示,两个表达蛋白均具有较好的抗原性.然后将N-1和N-2蛋白共同包被,建立了检测人血清中SARS病毒IgG抗体的间接ELISA法.用此方法检测120例临床诊断为SARS的病人和244个不同年龄组正常人血清IgG抗体,结果120例SARS病人的第一份血清IgG抗体总阳性率为60.0%,发病第0～7、8～10、11～14、15～27和28天后的血清中,SARS病毒IgG抗体阳性率分别为0、11.1%、60.0%、60.5%和70.3%;而244份正常人血清检测结果均为阴性,包括100份14岁以下儿童血清也未发现假阳性.结果表明,利用大肠杆菌表达的N蛋白完全能够替代全病毒灭活抗原,所建立的间接ELISA方法简单,价格低廉,能保证生物安全,对SARS可疑病例的确诊和排除具有重要的实际应用价值,可用于SARS高危人群的血清流行病学监测,SARS疫情的控制和预防,以及SARS病毒蛋白功能的研究.     

The orientations of core antenna chlorophylls in photosystem II are optimized to maximize the quantum yield of photosynthesis

The open reading frame 3 of the severe acute respiratory syndrome coronavirus (SARS-CoV) genome encodes a predicted protein 3a, consisting of 274 amino acids, that lacks any significant similarities to any known protein. We generated specific antibodies against SARS protein 3a by using a synthetic peptide (P2) corresponding to amino acids 261-274 of the putative protein. Anti-P2 antibodies and the sera from SARS patients could specifically detect the recombinant SARS protein 3a expressed in Escherichia coli and in Vero E6 cells. Expression of SARS protein 3a was detected at 8-12 h after infection and reached a higher level after approximately 24 h in SARS-CoV-infected Vero E6 cells. Protein 3a was also detected in the alveolar lining pneumocytes and some intra-alveolar cells of a SARS-CoV-infected patient's lung specimen. Recombinant protein 3a expressed in Vero E6 cells and protein 3a in the SARS-CoV-infected cells was distributed over the cytoplasm in a fine punctate pattern with partly concentrated staining in the Golgi apparatus. Our study demonstrates that SARS-CoV indeed expresses a novel protein 3a, which is present only in SARS-CoV and not in other known CoVs.     

Usefulness of IgG4 subclass antibodies for diagnosis of human clonorchiasis

The present study analyzed serum IgG subclass antibody reaction to major antigenic bands of Clonorchis sinensis to investigate improvement of its serodiagnosis. Of the four subclass antibodies, IgG1 and IgG2 antibodies were produced but not specific, IgG3 antibody was least produced, and IgG4 antibody was prominent and specific. The serum IgG antibody reaction to any of 43-50, 34-37, 26-28, and 8 kDa bands was found in 65.5% of 168 egg positive cases while IgG4 antibody reaction was found in 22.0% of them. The positive rates of IgG and IgG4 antibodies were directly correlated with the intensity of infection. All of the sera from heavily infected cases over EPG 5,000 showed positive reaction for specific IgG and IgG4 antibodies. The specific serum IgG4 antibody disappeared within 6 months after treatment. The bands of 35 kDa and 67 kDa cross-reacted with IgG antibodies but not with IgG4 antibodies in sera of other trematode infections. The present findings suggest that serum IgG4 antibody reaction to 8 kDa band is specific but not sensitive. Any method to increase its sensitivity is required for improved serodiagnosis.     

SARS冠状病毒的分离培养与鉴定

采集急性期病人的咽拭子或漱口液,用Vero、Vero E6、MDCK、Hela、Hep-2等传代细胞,人胚肺二倍体细胞(HEL)和人胚肺(HP)细胞分离培养严重急性呼吸系统综合症(SARS)的病原体。结果用Vero、Vero E6、MDCK和HP细胞从标本中分离到一株病毒。间接免疫荧光试验发现,恢复期病人血清可与所分离的病毒起反应,在胞膜和胞浆中出现翠绿色荧光;中和试验结果表明,恢复期病人血清能中和病毒对细胞的致细胞病变作用;电镜下可观察到冠状病毒样颗粒;RT-PCR法可扩增到冠状病毒特异性基因片段,且其核苷酸序列与国内外发表的SARS冠状病毒(SARS-Cov)相应的基因序列相符,同源性达到100％。从传染性非典型肺炎病人的漱口液中分离到SARS冠状病毒,这种病毒与传染性非典型肺炎密切相关。     

Study of interaction between IgG and IgM antibodies against rubella virus by the immunofluorescence method.

In immunoglobulin fractions or after elimination of IgG by absorption the immunofluorescence test for rubella IgM antibodies is more sensitive than in whole serum. Blocking of IgM activity by IgG antibodies was eliminated when the time of incubation of the serum with virus antigen was prolonged. After prolonged incubation higher titres of rubella antibodies were also obtained in the IgM immunoglobulin fractions. Protein A in Staphylococcus aureus suspension effectively absorbs antibodies of IgG class. The IgM antibody titres in absorbed sera of patients infected with rubella were in some cases 2 to 4 times higher than in unabsorbed sera.